A genome-wide transcriptome analysis in SETD2 deficient and proficient primary clear cell renal cell carcinoma (ccRCC) tumors revealed that splicing defects or alternative splicing events such as intron inclusion and differential exon usage are widespread in SETD2 deficient tumors [171]. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.